Dr. Washington Loses DEA Privileges After State License Revocation
Published Date: 7/8/2025
Notice
Summary
Dr. William Washington lost his medical license in Washington state, so the DEA is officially taking away his permission to handle controlled substances. Since he didn’t ask for a hearing, the DEA’s decision is final and immediate. This means Dr. Washington can no longer legally prescribe or manage controlled drugs, effective right now.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Dr. Washington
The DEA revoked William Washington, M.D.'s Certificate of Registration No. FW5625213, so he can no longer legally prescribe, dispense, or handle controlled substances. The Washington medical license was permanently revoked on November 26, 2024, an Order to Show Cause was served January 22, 2025, and the DEA Order revoking the DEA registration is effective August 7, 2025.
Pending DEA Applications Denied
The DEA denied any pending applications of William Washington, M.D., to renew or modify Certificate of Registration No. FW5625213 and denied any other pending application for additional registration in Washington. That denial is part of the Order effective August 7, 2025.
Fifteen-Day Reconsideration Right
The registrant may file a properly supported motion for reconsideration of the factual finding that he is not licensed to practice medicine in Washington within fifteen calendar days of the date of this Order. Any such motion and response must be filed and served by email to the other party and to the DEA Office of the Administrator at [email protected].
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-13825 — Designation of Phenethyl Halides as List I Chemicals
The DEA wants to add phenethyl halides to a special list of chemicals that are closely watched because they can be used to make illegal fentanyl. This means anyone handling these chemicals will have to follow new rules starting soon, no matter how much they have. If you work with these chemicals, get ready to comply and share your thoughts by August 10, 2026!
2026-13821 — Schedules of Controlled Substances: Placement of Tianeptine in Schedule I
The DEA wants to put tianeptine, a drug with potential risks, into Schedule I, meaning it’ll be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or uses tianeptine, bringing strict rules and penalties. You’ve got until August 7, 2026, to share your thoughts before the new rules could kick in.
2026-13705 — Importer of Controlled Substances Application: Benuvia Operations, LLC.
Benuvia Operations, LLC wants to become an official importer of certain controlled substances like marijuana extract and psilocybin. People and companies involved with these drugs can share their thoughts or ask for a hearing by August 6, 2026. This move could shake up who gets to bring these substances into the U.S., so keep an eye on the deadline if you’re interested!
2026-13581 — Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I
Starting July 6, 2026, the DEA plans to temporarily put three substances related to 7-hydroxymitragynine—Mitragynine Pseudoindoxyl, MGM-15, and MGM-16—into Schedule I, the strictest drug category. This means anyone making, selling, or using these chemicals will face tough legal rules and penalties. The move aims to control these substances quickly while the DEA studies them further, affecting businesses and researchers handling these compounds.
Previous / Next Documents
Previous: 2025-12607 — Bayer CropScience: Availability of a Petition for a Determination of Nonregulated Status and Draft Plant Pest Risk Assessment for MON 95275 Maize (Corn)
Bayer CropScience wants permission to grow a new type of corn called MON 95275 that protects itself from pesky corn rootworms using special proteins. The government is sharing the petition and a safety check for everyone to review and comment on. Farmers, consumers, and anyone interested can weigh in before a final decision is made, which could change how corn is grown and protected.
Next: 2025-12609 — Tanya Newlove, N.P.; Decision and Order
Tanya Newlove, a nurse practitioner from Illinois, lost her DEA registration because her state licenses expired and she didn’t ask for a hearing to defend herself. This means she can no longer handle controlled substances legally, effective immediately. If you’re a healthcare provider, this reminds you to keep your licenses current or risk losing important permissions.